We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Therapeutic Strategy for Microplastics and Nanoplastics: A Systems-Level Framework for Mitigation, Inflammation, and Companion Diagnostics
AI summary Read the abstract
A company document from Cythera Bio describing a planned framework for products aimed at micro- and nanoplastic exposure. The approach centers on particle aggregation, sequestration and inflammation pathways, not on breaking plastic down. It reports no experimental results.
Abstract Microplastics and nanoplastics (MPs/NPs) are increasingly recognized as biologically active environmental particulates capable of interacting with multiple organ systems. While current research has largely focused on environmental detection and polymer degradation, emerging evidence suggests that chronic particulate exposure may contribute to inflammation, barrier dysfunction, immune dysregulation, and altered biological signaling across gastrointestinal, neurological, metabolic, and systemic pathways. Cythera Bio is developing a systems-level therapeutic framework focused on reducing the biological impact of MPs/NPs through interaction-mediated mitigation, inflammatory modulation, and biologically adaptive therapeutic architectures. Rather than relying exclusively on polymer degradation, this framework emphasizes reduction of particle interaction potential through aggregation, sequestration, altered transport dynamics, barrier stabilization, and modulation of downstream inflammatory pathways. The company is pursuing both wellness-oriented exposure support products and FDA-regulated therapeutic programs spanning gastrointestinal disease, neuroinflammation, aging-associated dysfunction, and systemic inflammatory biology. Companion diagnostic and monitoring frameworks may further support exposure characterization and future adaptive therapeutic strategies.
More Papers Like This
Therapeutic Strategy for Microplastics and Nanoplastics: A Systems-Level Framework for Mitigation, Inflammation, and Companion Diagnostics
AI summary Read the abstract
Tiny plastic particles from our environment may be quietly triggering inflammation, weakening protective barriers in our gut and brain, and disrupting normal body signaling—not just polymer buildup, as once assumed. A biotech company called Cythera Bio is proposing a new treatment approach that doesn't try to break down these plastics, but instead works to trap them, stop them from moving through the body, strengthen tissue barriers, and calm the inflammation they cause. This is an early-stage framework rather than a finished treatment, but it points toward future products—both wellness supplements and prescription therapies—aimed at reducing the health
Direct and Indirect Mitigation Strategies for Microplastic and Nanoplastic Exposure: A Conceptual Framework for Combination Therapeutic Development
AI summary Read the abstract
A technical note setting out a framework for future research on micro- and nanoplastic exposure. It separates direct strategies, aimed at particle levels or their contact with tissue, from indirect ones aimed at downstream effects such as inflammation. The authors state that the purpose is not to claim demonstrated clinical efficacy.
Direct and Indirect Mitigation Strategies for Microplastic and Nanoplastic Exposure: A Conceptual Framework for Combination Therapeutic Development
AI summary Read the abstract
Tiny plastic particles from our environment may get into our bodies and contribute to inflammation, stress on cells, immune problems, and even brain and heart issues over time. This paper doesn't test new treatments—instead, it proposes a game plan for future research: combining strategies that reduce how much plastic gets into our tissues with treatments that calm the harmful effects those particles might cause. It's an early-stage roadmap for scientists, not a proven fix, but it highlights why tackling microplastic exposure may eventually require a two-pronged medical approach.
Therapeutic Opportunities in Microplastic- and Nanoplastic-Associated Neuroinflammation A Mechanism-Guided Analysis of Drug Development, Repurposing, and New-Indication Opportunities
AI summary Read the abstract
Tiny plastic particles from our environment may get into the body and trigger inflammation in the brain through several possible pathways, like stressing cells, weakening the brain's protective barrier, and disrupting gut-brain communication. This paper reviews existing research on these mechanisms, rather than presenting new experiments, and argues that understanding them could help scientists identify new drug targets or repurpose existing medications to protect brain health. It's important to note this is early-stage thinking: the biological pathways are plausible, but scientists still need more research to confirm how much microplastics actually affect human brain disease.
Microplastics in human body: accumulation, natural clearance, and biomedical detoxification strategies
AI summary Read the abstract
This review covers how microplastics enter the human body through air, water and food, and where they accumulate. It assesses what is known about how the body handles the particles on its own, including immune responses, and finds the evidence limited. It also surveys proposed biomedical approaches, none of them established.
Research digests by email
When a large batch of papers lands in the Atlas, we read through it and send a short write-up of what stood out.